ReviewCureus2022
Multiple Sclerosis and Autoimmunity: A Veiled Relationship.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Mathematical modeling in autoimmune diseases: from theory to clinical application.Frontiers in immunology · 2024Pooled it
- Central nervous system demyelination associated with biological agents used in the treatment of rheumatologic diseases: a retrospective cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Intermittent loss of anti-HBc antibodies in people with multiple sclerosis undergoing disease-modifying therapies.BMC infectious diseases · 2025Observational
- The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.Journal of neurology · 2025Article
- An inflammation-associated lncRNA induces neuronal damage via mitochondrial dysfunction.Molecular therapy. Nucleic acids · 2025Article
- Multiple Sclerosis After the Age of 50 Years: A Comparative Analysis of Late Onset and Adult Onset.Journal of clinical neurology (Seoul, Korea) · 2025Article
- From Multiple Sclerosis to Organ-Specific Autoimmune Disorders: Insights into the Molecular and Clinical Implications of Comorbidity.Molecular neurobiology · 2025Review
- Advances in Multiple Sclerosis.Biomedicines · 2025Article
- The Potential of Transcranial Direct Current Stimulation (tDCS) in Improving Quality of Life in Patients with Multiple Sclerosis: A Review and Discussion of Mechanisms of Action.Journal of clinical medicine · 2025Review
- Macrophage-targeted PEGylated liposomes ameliorate experimental autoimmune encephalomyelitis.Frontiers in immunology · 2025Article
- Mapping the genetic landscape of immune-mediated disorders: potential implications for classification and therapeutic strategies.Frontiers in immunology · 2025Article
- A Hypoxia-Inflammation Cycle and Multiple Sclerosis: Mechanisms and Therapeutic Implications.Current treatment options in neurology · 2025Review
- The immune tolerance role of Bregs in inhibiting human inflammatory diseases, with a focus on diabetes mellitus.Frontiers in immunology · 2025Review
- A multicenter, prospective cohort study on the anti-SARS-CoV-2 vaccination response in patients with multiple sclerosis in Germany.Frontiers in neurology · 2025Article
- Comprehensive analysis of the global impact and distribution of tick paralysis, a deadly neurological yet fully reversible condition.Clinical microbiology reviews · 2024Review
- Prevalence of comorbid autoimmune diseases and antibodies in newly diagnosed multiple sclerosis patients.Neurological research and practice · 2024Article
- The Role of Sex and Other Personal Characteristics in the Effects of Symptoms Severity on Self-Care Agency in Individuals with Multiple Sclerosis.Brain and behavior · 2024Article
- Mitophagy and cGAS-STING crosstalk in neuroinflammation.Acta pharmaceutica Sinica. B · 2024Review
- A perplexing case report of concomitant multiple sclerosis and myasthenia gravis.Annals of medicine and surgery (2012) · 2024Article
- Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis.Diseases (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an autoimmune inflammatory illness that affects the central nervous system (CNS) when the body's immune system attacks its tissue. It is characterized by demyelination and varying degrees of axonal loss. This article has compiled various studies elaborating MS and other autoimmune diseases (ADs) co-occurrence. Several conditions that fall into this category, including type 1 diabetes (T1D), rheumatoid arthritis (RA), Guillain-Barre syndrome (GBS), myasthenia gravis (MG), and many others, are found in MS patients and their relatives, suggesting one or more common etiologic mechanisms, including genetic, environmental, and immunological factors, supporting the concept of a possible influence of poly-autoimmunity on MS and the rest of ADs, as well as providing a significant feature for early detection of the disease and also a potential treatment option by clinical neurologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.